Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs VNET Group Inc — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.33 (market cap $2.27B), while VNET Group Inc trades at $5.26 (market cap $1.47B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| SLS | VNET | |
|---|---|---|
Market Cap | $2.27B | $1.47B |
Volume | 4,179,659 | 4,955,295 |
Sector | Health | Technology |
52-Week High | $15.46 | $14.03 |
52-Week Low | $1.39 | $5.13 |
Enterprise Value | $2.14B | $5.04B |
Typical Hold Time | — | 16 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VNET trades at $5.39, near a 52-week low, with a bearish technical signal and negative earnings misses in recent quarters. The company reported a net loss of $256.77 million in 2025, with a negative net income margin of -22.18%, though revenue grew to $9.95 billion. Positive cash flow from operations of $1.92 billion and a strategic investment closing in September 2026 provide some operational stability amid financial challenges.
The outlook remains cautious due to persistent losses and high leverage, but analyst consensus is moderately bullish with 62.5% buy ratings. Key risks include balance sheet pressures and competitive threats in the data center market, while potential upside hinges on execution of new capacity and AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
